Cargando…

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Convalescent plasma is currently one of the leading treatments for COVID-19, but there is a paucity of data identifying therapeutic efficacy. A comprehensive analysis of the antibody responses in potential plasma donors and an understanding of the clinical and demographic factors that drive variant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Sabra, Pekosz, Andrew, Park, Han-Sol, Ursin, Rebecca, Shapiro, Janna, Benner, Sarah, Littlefield, Kirsten, Kumar, Swetha, Naik, Harnish Mukesh, Betenbaugh, Michael, Shrestha, Ruchee, Wu, Annie, Hughes, Robert, Burgess, Imani, Caturegli, Patricio, Laeyendecker, Oliver, Quinn, Thomas, Sullivan, David, Shoham, Shmuel, Redd, Andrew, Bloch, Evan, Casadevall, Arturo, Tobian, Aaron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325184/ https://www.ncbi.nlm.nih.gov/pubmed/32607519 http://dx.doi.org/10.1101/2020.06.26.20139063

Ejemplares similares

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
por: Benner, Sarah E, et al.
Publicado: (2020)

Absence of pathogenic viruses in COVID‐19 convalescent plasma
por: Kandathil, Abraham J., et al.
Publicado: (2022)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Natarajan, Harini, et al.
Publicado: (2021)

SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy
por: Natarajan, Harini, et al.
Publicado: (2020)

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality
por: Morgenlander, William, et al.
Publicado: (2020)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
por: Heaney, Christopher D., et al.
Publicado: (2021)

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers
por: Heaney, Christopher D., et al.
Publicado: (2021)

Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2
por: Natarajan, Harini, et al.
Publicado: (2021)

Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2
por: Natarajan, Harini, et al.
Publicado: (2022)

CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
por: Redd, Andrew D, et al.
Publicado: (2021)

Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals
por: Redd, Andrew D, et al.
Publicado: (2021)

CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants
por: Redd, Andrew D, et al.
Publicado: (2021)

Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
por: Redd, Andrew D., et al.
Publicado: (2022)

Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
por: McConnell, Scott A., et al.
Publicado: (2023)

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
por: Patel, Eshan U., et al.
Publicado: (2020)

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers
por: Patel, Eshan U., et al.
Publicado: (2021)

A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels
por: Kruse, Robert L., et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
por: Li, Maggie, et al.
Publicado: (2022)

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
por: Gordon, Oren, et al.
Publicado: (2022)

LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
por: Li, Maggie, et al.
Publicado: (2022)

Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations
por: Park, Han-Sol, et al.
Publicado: (2023)

The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox
por: Bloch, Evan M., et al.
Publicado: (2022)

Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection
por: Shoham, Shmuel, et al.
Publicado: (2021)

Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment
por: Karaba, Andrew H., et al.
Publicado: (2023)

Early Outpatient Treatment for Covid-19 with Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2022)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

Durable SARS-CoV-2 B cell immunity after mild or severe disease
por: Ogega, Clinton O., et al.
Publicado: (2020)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection
por: Park, Han-Sol, et al.
Publicado: (2022)

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Sex-biased Immune Responses Following SARS-CoV-2 Infection
por: Ursin, Rebecca L., et al.
Publicado: (2020)

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
por: Randad, Pranay R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9v4fffpukepeh08p8jt57cnlj7